ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2018

Dec 12, 2018

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Living Cell Technologies Limited
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Ken Taylor

Date of last notice 31 August 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change		13 December 2018
No. of securities held prior to change		Unlisted options	Exercise Price	Expiry Date
		250,000	$0.100	01-Jul-20
		250,000	$0.100	01-Jul-21
		100,000	$0.140	01-Jul-20
		100,000	$0.190	01-Jul-21
		400,000	$0.075	04-May-19
		400,000	$0.100	04-May-19
		600,000	$0.113	01-Jul-19
		Total 2,100,000
Class		Unlisted Options
Number acquired		250,000 unlisted options

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed nil

Value/Consideration Exercisable at $0.0487 per option, vesting on 13 December Note: If consideration is non-cash, provide details and 2019 and expiring on 13 December 2021. estimated valuation

No. of securities held after change

Unlisted options	Exercise Price	Expiry Date
250,000	$0.100	01-Jul-20
250,000	$0.100	01-Jul-21
100,000	$0.140	01-Jul-20
100,000	$0.190	01-Jul-21
400,000	$0.075	04-May-19
400,000	$0.100	04-May-19
600,000	$0.113	01-Jul-19
250,000	$0.0487	13-Dec-21
Total 2,350,000

Nature of change Following shareholder approval at the annual general meeting Example: on-market trade, offheld on 15 November 2018, Dr Taylor has been issued 250,000 market trade, exercise of options, issue of securities options for nil consideration with an exercise price of $0.0487, under dividend reinvestment vesting on 13 December 2019 with an expiry date of 13 plan, participation in buy-back December 2021.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3